Original Paper

In Search for New Antipsoriatic Agents: NAD⁺ Topical Composition
A. Wozniacka^a, P. Szajerski^b, J. Adamus^b, J. Gebicki^b, A. Sysa-Jedrzejowska<sup>a

a</sup>Department of Dermatology, Medical University, Lodz,
^bInstitute of Applied Radiation Chemistry, Technical University, Lodz, Poland

Address of Corresponding Author

Skin Pharmacol Physiol 2007;20:37-42 (DOI: 10.1159/000096170)

  Key Words

• Nicotinamide adenine dinucleotide
• Psoriasis
• Antipsoriatic therapy

  Abstract

The aim of the study was to examine the effectiveness of the oxidized form of nicotinamide adenine dinucleotide (NAD⁺), adenosine precursor, in 37 patients suffering from psoriasis. As NAD⁺ is known to be relatively unstable, the second goal was to establish the proper conditions for the satisfactory stability of topical NAD⁺ composition. In each patient, two matching plaques were selected for the study. Topical treatment with 1 or 0.3% NAD⁺ in Vaseline ointment administered twice daily was compared with overnight therapy with 0.1% anthralin applied for 12 h and placebo. The enzymatic method was applied to determine the stability of NAD⁺ in Vaseline ointment. After a 4-week application, the reduction in erythema, infiltration and desquamation caused by 1 or 0.3% topical NAD⁺ composition was similar to the reduction caused by 0.1% anthralin. It was demonstrated that NAD⁺ underwent a considerable decomposition at room temperature, while it was sufficiently stable at 5°C; thus, for a longer use the agent should be stored at fridge temperature. NAD⁺ therapy combines good efficacy, cosmetic acceptability and convenient twice-daily application.

Copyright © 2007 S. Karger AG, Basel

  References

1.

Ashcroft DM, Li Wan Po A, Griffiths CE: Therapeutic strategies for psoriasis. J Clin Pharm Therap 2000;25:1-10.

2.

Müller K: Antipsoriatic and proinflammatory action of anthralin. Biochem Pharmacol 1997;53:1225-1221.

3.

Fogh K, Kragballe K: Recent developments in vitamin D analogs. Curr Pharm Design 2000;6:961-972.

4.

Brown JR, Cornell K, Cook PW: Adenosine- and adenine-nucleotide-mediated inhibition of normal and transformed keratinocyte proliferation is dependent upon dipyridamole-sensitive adenosine transport. J Invest Dermatol 2000;115:849-859.

5.

Levi-Schaffer F, Touitou E: Xanthines Inhibit 3T3 fibroblast proliferation. Skin Pharmacol 1991;4:286-290.

6.

Levi-Schaffer F, Dayan N, Touitou E: Diethylene glycol monoethyl ether (Transcutol) displays antiproliferative properties alone and in combination with xanthines. Skin Pharmacol 1996;9:53-59.

7.

Iancu I: Experimental treatment of psoriasis with compounds which increase the intracellular level of cAMP; thesis, Tel Aviv University, 1979.

8.

Kim UH, Han MK, Park BH, Kim HR, An NH: Function of NAD glycohydrolase in ADP-ribose uptake from NAD by human erythrocytes. Biochim Biophys Acta 1993;1178:121-126.

9.

Lee HC, Aarhus R: ADP-ribosyl cyclase: an enzyme that catalyzes NAD⁺ into a calcium-mobilizing metabolite. Cell Regul 1991;2:203-209.

10.

Travo P, Muller H, Shuber F: Calf spleen NAD glycohydrolase. Comparison of the catalytic properties of the membrane-bound and the hydrosoluble forms of the enzyme. Eur J Biochem 1979;96:141-149.

11.

Zimmermann H: Extracellular purine metabolism. Drug Dev Res 1996;39:337-352.

12.

Aleo MF, Sestini S, Pompuci G, Preti A: Enzymatic activities affecting exogenous nicotinamide adenine dinucleotide in human skin fibroblasts. J Cell Physiol 1996;167:173-176.

13.

Aleo MF, Gindici ML, Sestini S, Pompuci G, Preti A: Metabolic fate of extracellular NAD in human skin fibroblasts. J Cell Biochem 2001;80:360-366.

14.

Gbicki J, Marcinek A, Adamus J, Paneth P, Rogowski J: Structural aspects and rearrangement of radical cations generated from NADH analogues. J Am Chem Soc 1996;118:691-692.

15.

Gbicki J, Marcinek A, Zielonka J: Transient species in the stepwise interconversion of NADH to NAD⁺. Acc Chem Res 2004;37:379-386.

16.

Marcinek A, Adamus J, Huben K, Gbicki J, Bartczak TJ, Bednarek P, Bally T: Hydrogen-transferred radical cations of NADH model compounds. 1. Spontaneous tautomerization. J Am Chem Soc 2000;122:437-443.

17.

Wozniacka A, Sysa-Jdrzejowska A, Adamus J, Gbicki J: Topical application of NADH for the treatment of rosacea and contact dermatitis. Clin Exp Dermatol 2003;28:61-63.

18.

Ganti T, Fodor J: Studies on the kinetics of NAD-decomposition. Acta Physiol Acad Sci Hung 1965;26:199-205.

19.

Lawry OH, Passonneau JV, Rock MK: The stability of pyridine nucleotides. J Biol Chem 1961;236:2756-2759.

20.

Braun-Falco O, Plewig G, Wolf HH, Burgdorf WHC: Dermatology. Heidelberg, Springer, 2000, p 597.

21.

Unna PG: Cignolin als Heilmittel der Psoriasis. Dermatol Wochenschr 1916;62:116-137.

22.

Griffiths CE, Camp RD, Barker JN: Psoriasis; in Burns T, Breathnach S, Cox N, Griffiths C (eds): Rook's Textbook of Dermatology. Oxford, Blackwell Science, 2004, pp 35.1-35.69.

23.

Lowe NJ, Breeding J: Anthralin. Different concentration effects on epidermal cell DNA synthesis rates in mice and clinical responses in human psoriasis. Arch Dermatol 1981;117:698-700.

24.

Montes LF, Wilborn WH, Brody I: Low strength anthralin in psoriasis. J Cutan Pathol 1979;6:445-456.

  Author Contacts

Wozniacka Anna MD, PhD
Department of Dermatology, Medical University of Lodz
Krzemieniecka 5
PL-94-017 Lodz (Poland)
Tel./Fax +48 42 688 45 65, E-Mail wozniacka@bmp.net.pl

  Article Information

Received: September 29, 2005
Accepted after revision: April 21, 2006
Published online: October 11, 2006
Number of Print Pages : 6
Number of Figures : 4, Number of Tables : 2, Number of References : 24

  Publication Details

Skin Pharmacology and Physiology (Journal of Pharmacological and Biophysical Research)

Vol. 20, No. 1, Year 2007 (Cover Date: December 2006)

Journal Editor: Lademann, J. (Berlin)
ISSN: 1660-5527 (print), 1660-5535 (Online)

For additional information: http://www.karger.com/SPP

  Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.